» Articles » PMID: 15626577

Influence of Probenecid on the Delivery of Morphine-6-glucuronide to the Brain

Overview
Journal Eur J Pharm Sci
Specialties Chemistry
Pharmacology
Date 2005 Jan 1
PMID 15626577
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

The objective was to evaluate the influence of probenecid on the blood-brain barrier (BBB) transport of morphine-6-glucuronide (M6G). Microdialysis probes were placed in the striatum and into the jugular vein of Sprague-Dawley rats. Each probe was calibrated in vivo using retrodialysis by drug. M6G was administered as a 4-h exponential i.v. infusion, and the experiment was repeated the following day with the addition of probenecid. The data were analysed using NONMEM. An integrated model including the total arterial concentrations, the dialysate concentrations in brain and blood, and the recovery measurements, was developed. The extent of BBB transport, expressed as the ratio between clearance into the brain and clearance out of the brain (CL(in)/CL(out)), was estimated as 0.29 on both days, indicating that efflux transporters act on M6G at the BBB. However, the probenecid-sensitive transporters are not involved in the brain efflux, as the ratio was unaltered although probenecid was co-administered. In contrast, the systemic elimination of M6G decreased by 22% (p<0.05) upon probenecid co-administration. The half-life of M6G was longer in the brain than in blood on both experimental days (p<0.05). In conclusion, probenecid decreased the systemic elimination of M6G, but had no effect on the BBB transport of M6G.

Citing Articles

Do P-glycoprotein-mediated drug-drug interactions at the blood-brain barrier impact morphine brain distribution?.

Gulave B, Lesmana A, de Lange E, van Hasselt J J Pharmacokinet Pharmacodyn. 2025; 52(1):11.

PMID: 39776000 PMC: 11706904. DOI: 10.1007/s10928-024-09957-0.


PBPK-PD model for predicting morphine pharmacokinetics, CNS effects and naloxone antagonism in humans.

Mu R, Liu T, Liu X, Liu L Acta Pharmacol Sin. 2024; 45(8):1752-1764.

PMID: 38570601 PMC: 11272789. DOI: 10.1038/s41401-024-01255-2.


Revisiting Cerebrospinal Fluid Flow Direction and Rate in Physiologically Based Pharmacokinetic Model.

Hirasawa M, de Lange E Pharmaceutics. 2022; 14(9).

PMID: 36145511 PMC: 9504371. DOI: 10.3390/pharmaceutics14091764.


Modeling Blood-Brain Barrier Permeability to Solutes and Drugs In Vivo.

Bickel U Pharmaceutics. 2022; 14(8).

PMID: 36015323 PMC: 9414534. DOI: 10.3390/pharmaceutics14081696.


Understanding the Blood-Brain Barrier and Beyond: Challenges and Opportunities for Novel CNS Therapeutics.

de Lange E, Hammarlund Udenaes M Clin Pharmacol Ther. 2022; 111(4):758-773.

PMID: 35220577 PMC: 9305478. DOI: 10.1002/cpt.2545.